Acute Liver Failure: Science and Practice (RP2003B)

Dallas, TX US
March 30, 2020 to March 31, 2020

Acute liver failure (ALF) is a rare but devastating condition that arises from diverse etiologies, has a high mortality and requires high resource utilization including transplantation.

The Acute Liver Failure Study Group (ALFSG) has been funded by NIDDK since 1997 to collect detailed clinical data on more than 3,500 patients, and has recently closed its registry and database for enrollments. It is an opportune time to take stock, consider where the field of study of ALF is going, what has been accomplished and to determine future directions of research in this unique syndrome. The audience would include basic scientists that work on liver injury and clinicians (hepatologists, surgeons) who care for these very ill patients.

This two-day program will provide a comprehensive understanding of all aspects of the pathogenesis and treatment of ALF including possible future therapies. The initial day of the meeting will be devoted to allowing investigators to present work pertaining to pathogenesis and disease mechanisms. The second day of the meeting will be devoted to reviewing aspects of disease management including evaluation, treatment and consideration of prognosis, liver transplantation and liver support devices.​​​​​​
 

Poster abstract scholarship available for early-career investigators! 

The Acute Liver Failure Study Group, sponsor of the symposium, invites all students, residents, trainees and junior faculty (first five years) to submit an abstract for poster presentation at the symposium. The lead author of the top eight abstracts selected will be awarded coach travel, hotel and conference registration for this two-day meeting. Click here to apply!

 

This course/program is endorsed by AASLD.  The Acute Liver Failure Study Group is pleased to have received the endorsement of the American Association for the Study of Liver Diseases (AASLD). Copyright © 2020 by the American Association for the Study Diseases. All rights reserved.

DISCLAIMER
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

 

Target Audience

THIS ACTIVITY IS INTENDED FOR PROVIDERS IN THE SPECIALTIES OF: 
Anesthesiology
Critical Care Medicine
Gastroenterology and Hepatology
Surgery

Learning Objectives

  • Describe the differences between liver injury from Acetaminophen (APAP) vs. other drugs.
  • Restate the role of cytokines in relation to injury evolution.
  • Explain basic factors that promote liver regeneration.
  • Explain the concept of sterile inflammation.
  • Discuss different mechanisms of liver injury and the role of genomics in susceptibility to acute liver failure.
  • Describe the current state of genome wide association studies. Review current state of identification of single nucleotide polymorphisms (SNPs) for specific diseases/drug injuries
  • Review the elements of the basic and advanced work-ups for ALF patients.
  • Identify natural history, differences in presentation, and how etiology drives prognosis and transplant decisions.
  • Describe the circulatory and neurological physiology of ALF.
  • Explain new understanding regarding hemostasis in ALF, management of kidney injury and hemostasis.
  • Compare present treatment modalities and propose possible future management protocols.
  • Contrast the differences in presentation and outcome of different etiologies.
  • Relate how etiology drives prognosis and transplant decisions.
  • Envision novel approaches to managing ALF in the future.
  • Describe current issues surrounding liver support devices.
Course summary
Available credit: 
  • 12.25 AMA
  • 12.25 Attendance
Course opens: 
10/02/2019
Course expires: 
03/30/2021
Event starts: 
03/30/2020 - 7:00am
Event ends: 
03/31/2020 - 2:00pm
Cost:
$100.00

 

 

Monday, March 30, 2020 

 

TIME

 

TOPIC

SPEAKER

7:00 a.m.

8:00 a.m.

Registration/Breakfast

 

8:00 a.m.

10:15 a.m.

Session 1: Acute Liver Failure: Overview and Mechanisms of Liver Injury

Moderators: Brendan McGuire, M.D.,
William M. Lee, M.D.

 

 

Welcome and Introduction

Brendan McGuire, M.D.

 

 

Acute Liver Failure and ALFSG

William M. Lee, M.D.

 

 

Patterns of Liver Injury

Neil Kaplowitz, M.D.

 

 

Clinical Phenotypes of ALF

Raj Reddy, M.D.

 

 

Histopathology of ALF

David Kleiner, M.D.

 

 

SIRS and the Role of Infection in ALF

(TBD)

10:15 a.m.

10:30 a.m.

Break

 

10:30 a.m.

12:30 p.m.

Session 2: Liver Regeneration and Response to Injury

Moderators: Sanjeev Gupta, M.D.,
Michael Schilsky, M.D.

 

 

Overview of Basic Regenerative Mechanisms

Sanjeev Gupta, M.D.

 

 

Immunologic Basis of Liver Injury/Response

Mark McPhail, M.D.

 

 

Plasma Cells and Injury in HBV ALF

Patrizia Farci, M.D.

 

 

Bio-markers in ALF

Mike Schilsky, M.D.

12:30 p.m.

1:15 p.m.

Lunch

 

1:15 p.m.

2:45 p.m.

Session 3: Genomics of Liver Injury

Moderators: Raymond Chung, M.D.,
Robert Fontana, M.D.

 

 

Genomics Overview

Raymond Chung, M.D.

 

 

Genomics and Viral Liver Injury

Laurent Casanova, M.D.,PhD.

 

 

Genomics of Drug-Induced Liver Injury

Paola Nicoletti, Ph.D.

2:45 p.m.

3:00 p.m.

Break

 

3:00 p.m.

5:00 p.m.

Session 4: Diagnosis and Evaluation of ALF

Moderators: Jim Hanje, M.D.,
Dan Ganger, M.D.

 

 

Natural History of ALF

Ken Simpson, M.D.

 

 

Workup of Acute Liver Failure: Checklist

Oren Fix, M.D.

 

 

Case Presentation: New Diagnoses (HLH case)

Shannan Tujios, M.D.

 

 

Causality: Determining Etiology in ALF

Daniel Ganger, M.D.

 

 

 

Tuesday, March 31, 2020 

 

TIME

 

TOPIC

SPEAKER

7:00 a.m.

8:00 a.m.

Registration/Breakfast

 

8:00 a.m.

9:30 a.m.

Session 5: Complications of ALF: Riding Out the Storm

Moderators: Dean Karvellas, M.D.,
Jody Olson, M.D.

 

 

Critical Care of ALF: Overview

Dean Karvellas, M.D.

 

 

Hemostasis in ALF: Is There a Coagulopathy?

R. Todd Stravitz, M.D.

 

 

Fluids, Pressors, Kidney Injury Management

Jody Olson, M.D.

9:30 a.m.

9:45 a.m.

Break

 

9:45 a.m.

12:00 p.m.

Session 6: Prognosis in ALF/Role of Transplantation

Moderators: Ken Simpson, M.D.,
David Koch, M.D.

 

 

Prognostic Indices: Determining Outcomes

David Koch, M.D.

 

 

Designing Clinical Trials in an Orphan Disease

Valerie Durkalski, Ph.D.

 

 

Methacetin Breath Test and Other Tools

Robert Fontana, M.D.

 

 

Outcomes of Transplantation: SRTR and ALFSG

Justin Parekh, M.D.

 

 

Is ALF Going Away? An Epidemiologist’s View

Baback Orandi, M.D.

12:00 p.m.

1:00 p.m.

Lunch

 

1:00 p.m.

2:00 p.m.

Session 7: The Future of ALF: Newer Modalities of Liver Support

Moderators: R. Todd Stravitz, M.D.,
Scott Nyberg, M.D.

 

 

Liver support machines: Current status

Scott Nyberg, M.D.

 

 

Stem cell recruitment for liver support

Russell Wesson, M.D.

 

 

Final words

William M. Lee, M.D.

 

UT Southwestern Medical Center - T. Boone Pickens Biomedical Building Auditorium (NG3.112)
6001 Forest Park Rd.
Dallas, TX 75235
United States

Parking: The parking garage is located adjacent to the T. Boone Pickens Biomedical Building. The garage entrance is to the right of the front building entrance. Use elevator to third floor and follow direction signs to the conference room.

Program accessibility: We accommodate people with disabilities. Please call 214-648-2166 for more information. To ensure accommodation, please register as soon as possible.

Course Directors:

William Lee, M.D.
Meredith Mosle Chair in Liver Disease in Honor of Dr. William M. Lee
Professor of Internal Medicine
UT Southwestern Medical Center

Brendan McGuire, M.D.
Medical Director of Liver Transplant
Professor
The University of Alabama at Birmingham
 

Planning Committee Members:

R. Todd Stravitz, M.D.
VCU Health

Robert J. Fontana, M.D.
University of Michigan Medical School

A. James Hanje, M.D.
The Ohio State University Wexner Medical Center

Constantine Karvellas, M.D.
University of Alberta

Jody Olson, M.D.
The University of Kansas Medical Center

The University of Texas Southwestern Medical Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Texas Southwestern Medical Center designates this live activity for a maximum of 12.25 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

 

This course/program is endorsed by AASLD.  The Acute Liver Failure Study Group is pleased to have received the endorsement of the American Association for the Study of Liver Diseases (AASLD). Copyright © 2020 by the American Association for the Study Diseases. All rights reserved.

DISCLAIMER
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Available Credit

  • 12.25 AMA
  • 12.25 Attendance

Accreditation Period

Course opens: 
10/02/2019
Course expires: 
03/30/2021

Price

Cost:
$100.00
Please login or create an account to take this course.

REGISTRATION

  • Physicians and General Registration $100
  • Trainees $50
  • Full-time UTSW Faculty and Staff ONLY - Complimentary

To register:

  1. Create an account in EthosCE, online learning management system, by selecting the "create an account" link at the bottom of the page or "log-in" to your existing account.
  2. Return to this course page, click "Register" tab, and select the designated fee.
  3. In the following "checkout" pages you will verify and process your payment.
  4. After registration is completed, a confirmation will be sent by email.

How to use your coupon code?
 

Refund Policy:

A $25 handling fee will be deducted from cancellation refunds. Refund requests must be received by email at cmeregistrations@utsouthwestern.edu by March 13, 2020. No refunds will be made thereafter.

**Limited onsite registration will be available